---
AWKN-002

About

AWKN-P002 - a novel psychedelic MAT consisting of a patent pending proprietary S-Ketamine formulation, administered sub-lingually via an oral thin film (OTF), used in combination with manualized relapse prevention CBT to treat AUD in the US.

Status:

• Awakn has in-licensed a successfully completed Ph1 program with patents filed international and with global exclusivity for addiction, anxiety, and eating disorders

Goals:

• Target an FDA 505(b)(2) pathway
• Progress AWKN-002 to late clinical stage and seek commercial opportunities

IP:

• S-ketamine OTF patents filed in US, China, Canada, Europe, and Japan

Sign Up for Newsletter

MAIN OFFICE
Awakn Life Sciences Corp.
301-217 Queen St. W
Toronto, Ontario M5V 0R2
Canada

© 2023 Awakn Life Sciences Corp      |      Privacy Policy      |      Disclaimer